merck keytruda post solid data renal cancer open
anoth growth avenu drug
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
adept partnership acquisit bristol-my squibb
built strong portfolio drug robust pipelin
compani face signific continu gener pressur virolog
drug expect next gener drug fill
patent hole near term support wide moat
steadi growth potenti sell busi line
unrel core pharmaceut strategi compani
streamlin focu primarili specialti pharmaceut
bristol creat strong pipelin brought partner
share develop cost diversifi risk clinic
regulatori failur believ cardiovascular partnership
repres one import partnership manag
blockbust potenti eliqui atrial fibril
bristol discov drug intern like strateg
partner decis move reduc risk lower
develop market cost
within pipelin bristol astut acquisit medarex help
cancer
immunotherapi yield sever major blockbust
compound bristol cancer drug opdivo hold potenti
revolution cancer treatment develop
multi-billion-dollar opportun base solid efficaci
combin potenti drug strong price power
bristol first-mov advantag space
translat leadership market share
bristol aggress reposit expand
challeng patent loss compani shed diabet
busi medic imag group wound-car divis
nutrit busi effort focu high-margin
specialti drug group recent move acquir celgen move
bristol significantli specialti pharmaceut
segment market celgen drug larg target cancer
tend area strong drug price power
help bristol maintain drug price abil time
gover privat payer push back drug cost
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
bristol-my squibb discov develop market drug variou
indic cardiovascular oncolog immun disord key
focu bristol immuno-oncolog firm lead drug
develop unlik diversifi peer bristol exit
sever nonpharmaceut busi focu brand specialti drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
merck keytruda post solid data renal cancer
open anoth growth avenu drug feb
merck report posit keytruda data combin
inlyta first-lin renal cancer open anoth
growth opportun drug outsid lung cancer
lung cancer remain biggest opportun
keytruda project renal cancer drug sale immuno
oncolog drug reach billion annual
howev expect major chang fair
valu estim merck bristol hold compet
renal cancer opdivo plu yervoy
nevertheless continu strong data multipl cancer
reinforc strength keytruda across multipl
indic provid merck strong pillar support
wide moat
project data drive close market share
merck keytruda renal cancer detail data
present genitourinari cancer
symposium summari overal surviv data
improv look like strongest data report
renal cancer far howev rate side effect
grade partli concern given lethal natur
diseas expect keytruda gain market share
like stronger gain patient low
express opdivo lack competit data expect
bristol opdivo plu yervoy retain close remaind
first-lin renal cancer market despit slightli wors
surviv benefit overal surviv benefit
benefit patient combin better
side-effect profil patient side effect
grade first-mov advantag approv
april also opdivo gain approv later line
renal cancer sever year ago set strong
entrench physician commun also pfizer
partner merck kgaa roch look gain approv
treat renal cancer immuno oncolog drug
limit data regimen look
detail look immuno oncolog
landscap pleas see annual pipelin report annual
drug pipelin report moat remain secur innov
counter price gener headwind
increas bristol fair valu estim
due valu creat expect celgen
focus oncolog therapeut area overlap
billion annual cost synergi expect
major sg like commerci overlap
overhead make deal posit strateg also
celgen deal diversifi bristol oncolog portfolio
think reduc risk around signific number
late-stag immuno oncolog readout bristol given
bristol
launch
immuno-oncolog drug larger import
indic first-lin nsclc catch
combin treatment import despit
increas challeng larg nsclc market bristol
remain well-posit melanoma renal cancer
although compani face sever patent loss
next year continu strong convict
pipelin expand celgen acquisit led
opdivo potenti significantli alter
treatment paradigm sever major cancer set
project drug reach risk-adjust peak sale close
billion also eliqui cardiovascular diseas
continu grow despit alreadi develop
major blockbust base lead efficaci solid
look whole compani expect averag
annual earn per share growth next five year
help celgen acquisit expect margin
expand high margin celgen drug fold
bristol portfolio high royalti rate paid eliqui
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
base wide line-up patent-protect drug
entrench salesforc economi scale bristol
firm price drug level translat superior
return invest capit compar cost
particularli cancer drug area focu bristol
patent also provid bristol ampl time bring
forward next gener new drug addit
sever bristol current market drug biolog
creat addit hurdl gener firm cost
develop market biosimilar much higher
typic gener small molecul mani
entrench salesforc enabl firm partner
smaller drug compani gain access extern creat
drug augment intern drug-develop effort
addit bristol sheer size gener strong
stabl cash flow requir fund approxim
million need averag bring new drug
major patent cliff time period bristol
competit advantag stabil moat trend
stabil result combin fewer upcom
patent loss combin stronger pipelin
pipelin side bristol first-mov advantag
immuno-oncolog set set sever major
blockbust carri high margin
patent protect well next decad project
immuno-oncolog drug off-set patent
loss next four year addit bristol
late-stag pipelin exclus focus unmet medic
need specialty-car indic area debilit
lethal diseas pipelin focu help increas
research develop product fight back
increasingli risk-avers food drug
weigh gross margin firm longer
term expect earn fall begin
time period gener pressur key drug revlimid
eliqui emerg
inelast product portfolio
larg base low volatil cash flow
divers
bristol-my uncertainti medium higher
pharma peer group partli high product
bull case probabl
estim rel base case scenario analysi
show moder varianc henc medium uncertainti
rate key factor affect scenario analysi
includ degre success brand drug pipelin
along magnitud competit pressur
current market drug opdivo biggest driver
valuat far rang outcom drug drive
signific portion chang valuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
administr well increas reluct
part insur compani govern payer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
obristol growth prospect focus cancer drug
opdivo cardiovascular drug eliqui
well posit versu competit
osom patent loss weigh compani
next coupl year creat slight headwind
oth oncolog drug opdivo hold potenti
radic shift treatment paradigm sever
cancer indic result peak sale
billion annual
owe believ larg portion bristol valuat tie
cancer drug opdivo could amplifi
neg impact stock clinic data poor
competitor report superior data opdivo
omor half bristol late-stag pipelin focus
immunolog cancer -- indic
fda aggress approv drug typic
obristol recent move acquir celgen add
signific debt patent exposur
gener revlimid like
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
bristol carri fairli solid financi structur
debt/ebitda project close time howev
recent move acquir celgen expect
debt/ebitda go close time expect
metric fall bristol like
pay debt fairli quickli follow acquisit
bristol cashflow combin celgen cashflow
put firm solid finan foot
worst patent loss begin time
bristol increas focu brand drug sell
unrel busi line elev exposur
patent loss increas brand drug focu
rais compani depend pipelin
result higher sale volatil observ
diversifi peer addit compani expos
risk face entir pharmaceut group includ
gener threat decreas price power owe
managed-car constraint product liabil case
product-specif standpoint believ compani
largest pipelin risk surround immunotherapi drug
could develop major blockbust fail
market depend clinic data risk
competitor merck roch take market
share immunotherapi rise compani
catch particularli combin therapi lastli
recent move acquir celgen add finan risk due
larg amount debt need deal overal
view compani uncertainti medium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
follow relinquish ceo post lamberto
andreotti giovanni caforio took
ceo view success plan natur progress
andreotti year old transit occur
decad experi pharmaceut industri
doctor caforio bring strong skill set top
posit round top spot cfo charl bancroft
chief scientif offic tom lynch bring solid experi
leadership role bancroft bring solid bristol
tenur join compani held
posit increas respons financ
lynch bring decad academ industri experi
primarili massachusett gener hospit post
stewardship front rate current manag
standard sever acquisit medarex
excel use capit deal like inhibitex
amylin repres overpay asset also
posit side bristol aggress cut cost
adapt scale follow patent loss believ
help open capit reinvest busi
cut cost bristol still provid
signific fund toward research develop
effort key creat next gener drug
support high return invest capit recent
move acquir celgen test stewardship
import given heavi use debt equiti
believ deal like creat minor valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bristol post steadi offer posit opdivo
match consensu expect earn
stronger expect anticip
major chang fair valu estim base
result earn beat partli base lower-than-
expect research develop spend
guidanc larg line expect
continu view stock under-valued celgen
deal creat valu strong revlimid cash flow
expand bristol pipelin core pillar wide moat
quarter bristol largest drug opdivo sale
post strong year-over-year growth sequenti
growth slow almost flat
probabl
repres drug growth
manag guid opdivo growth expect
drug post larg flat growth strength renal
cell cancer melanoma offset declin sale
second-lin lung cancer beyond expect opdivo
return growth continu market share gain renal
cancer melanoma well expand indic
lung brain liver gastric cancer importantli bristol
withdrew first-lin lung cancer applic food
drug administr need data support
file expect support lung data three
part first half
surviv data patient part
surviv data patient checkmat
surviv data patient -- strong data
merck keytruda like limit opdivo lung cancer
share close
regard celgen acquisit manag reiter
convict benefit deal believ
underappreci pipelin creat valu bristol
bullish multipl sclerosi drug ozanimod
car-t drug liso-cel due potenti better safeti
complet review bristol celgen pipelin
secur
innov counter price gener
headwind acceler
bristol-my squibb celgen merg
billion deal think repres logic buildout
bristol pipelin oncolog immunolog
obviou therapeut area overlap billion annual
cost synergi expect major sg
like commerci overlap overhead think
deal posit strateg financi prior deal
saw celgen near-term pipelin significantli
under-valued estim billion sale
firm late-stag pipelin roughli billion
higher consensu bristol manag note
conserv stanc revlimid patent expir
think could fit view
assum singl gener entri teva sever
gener launch time frame
bristol plan acquir celgen combin
cash per share one share bristol stock per celgen
share total valu per share give bristol
sharehold combin firm
addit cvr worth per celgen share ozanimod liso-
cel receiv fda approv within reason
time frame deal board approv firm
expect close third quarter
expect slightli lower per share celgen fair
valu estim match offer price expect
major chang per share bristol fair valu
estim factor up-front deal price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oncolog bristol portfolio heavili depend
opdivo growth competit merck keytruda
particularli largest lung cancer segment limit
bristol oncolog portfolio think reduc risk
around signific number first-lin lung cancer data
readout opdivo expect expect
bristol experi sprycel cml could overlap
pomalyst help celgen expand reach new
market revlimid expans nhl file
expect shortli bristol early-mov advantag
opdivo could also help combin firm evalu
potenti combin regimen sever differ
modal car-t celgen liso-cel small
molecul next-gener imid early-stag test
bristol appear press hard celgen early-
stage pipelin sever phase program bcma
therapi well imid
enter pivot studi
immunolog bristol success orencia could support
celgen otezla market effort head-to-head
trial otezla bristol progress data
expect bristol foundat psoriasi
prior launch ozanimod entri ms launch
expect new market celgen
bristol ozanimod potenti
ibd ozanimod phase uc crohn
phase crohn
next four year help bristol reduc leverag
prepar commerci sever drug
candid end
bristol post neg immuno oncolog data
smaller cancer set lead fve cut
bristol-my report disappoint phase data
checkmat small cell lung cancer sclc
opdivo yervoy lead fair valu estim cut
drug combin continu look
well posit melanoma renal cancer failur
show surviv benefit sclc reduc peak sale
bristol immuno oncolog drug billion
close million annual nevertheless
bristol solid posit immuno oncolog
indic combin strong portfolio
market pipelin drug continu support wide
disappoint result checkmat follow mix
earlier data refractori sclc set partli base
strong data checkmat studi bristol gain
approv opdivo refractori sclc august
set expect posit data checkmat
healthier patient popul howev
disappoint sclc data checkmat suggest
opdivo may much benefit seen early-
stage studi poor result checkmat hurt
bristol immuno oncolog franchis smaller cancer
indic remind sclc repres close
lung cancer accord american cancer
discuss octob celgen win fight
preserv post-revlimid moat model
celgen cash flow oper grow north
billion year ahead revlimid patent
expir think revlimid strong growth prospect
given strong data emerg roch tecentriq
merck keytruda sclc expect bristol gain
much market share sclc set opdivo
still like hold small share sclc market
expect roch merck gain lion share sclc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market immuno oncolog drug expect
chang sale project cancer indic
believ result mani implic
type cancer
deeper dive outlook opdivo competit
immuno-oncolog drug pleas see june report
bristol-my pleas note recent stock
appreci view merck closer fairli valu
oct presid trump outlin potenti action
price drug cover medicar part
administ hospit physician offic
weigh investor sentiment surround government-
led drug price reform announc time
ahead novemb elect follow trump
sign yesterday support bill fight opioid
epidem make fair valu chang
result announc sever signific
uncertainti make difficult assum signific
hit price first remain unclear whether result
actual reform propos industri reaction
comment period run end
could neg smaller fail
effort tweak part price obama
time impact also question demonstr
drug could start would
surpris implement delay beyond trump
first term
increas uncertainti around
implement addit unclear drug would
specif target drug high part
spend similar price intern market see
immuno-oncolog drug ultra orphan diseas
therapi clear geographi would
particip initi demonstr project although
intend cover part spend final
compensatori price increas outsid could help
pharma/big biotech firm signific
exposur medicar part begin discuss
healthcar observ drug price reform
weigh valuat moat look secur drug
biotech industri look under-valued estim
firm highest exposur percentag drug
bristol-my squibb
sever new piec inform releas today
includ advanc notic propos rulemak
anprm hh report part drug price rel
price develop nation new council
date drug price
anprm follow request inform juli
part larger propos medicar outpati payment
rule allud possibl medicar part
demonstr project anprm discuss potenti
lower part spend save billion six-
year period use intern price
index model base basket intern price
privat sector negoti model would phase
 price five-year period begin spring
focus drug highest part spend
could initi target drug first two year
model one reliabl data intern drug
price target price would lower overal would
vari depend drug price intern market
privat sector negoti competit acquisit
program implement fail think
size part program today could give greater
likelihood success could make part similar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
part privat sector negoti via pbm help
control price
today hh report offer detail analysi
intern price highest-sel part
therapi conclud intern price
develop market larg europ canada japan
lower price basket drug
account part spend hh report note
biggest save could seen lower price
rituxan alreadi pois see biosimilar entrant
first half well neulasta also
face biosimilar threat ophthalmolog drug
regeneron eylea roch lucenti
report highlight trend drug approv
drug spend trump administr start
faster gener brand drug approv rate
also includ analysi support administr
impact price lower rate brand drug price
growth larger discount brand drug sinc earli
quarter strong growth opdivo
cardiovascular drug eliqui help off-set gener
pressur older virolog drug lead overal sale
growth expect growth moder
next three year expect opdivo growth slow
significantli base fewer avail patient
second-lin immuno-oncolog treatment non-small-cel
lung cancer given merck keytruda recent gain
approv first-lin nsclc patient major
market believ unlik patient use opdivo
follow failur keytruda given similar
drug howev bristol remain well posit renal
skin cancer support close half total opdivo sale
still view opdivo well posit second-
line lung cancer potenti
first-lin nsclc patient repres close
first-lin nsclc market opportun data
expect clarifi opdivo
potenti first-lin nsclc also drug hold potenti
treat liver small-cel lung brain cancer
sever studi read next month
buoy strong opdivo eliqui sale bristol post
solid futur growth slow oct
bristol-my squibb report third-quart sale line
consensu expect bottom line
stronger expect partli due increas
royalti dont expect major chang fair
valu estim base result follow recent
slide stock price view bristol under-valued
despit increas competit clinic data merck
keytruda bristol
immuno-oncolog platform
continu view bristol immuno-oncolog drug opdivo
yervoy well posit gain close one fourth
immuno-oncolog market strength
immuno-oncolog also cardiolog immunolog
deeper dive outlook opdivo competit
immuno-oncolog drug pleas see june report
bristol-my pleas note recent stock
appreci view merck fairli valu
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
